- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00401921
A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy
A Randomized, Placebo-Controlled Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy
The primary aim of this protocol is to investigate a possible new, neuroprotective treatment to prevent cognitive deficits that occur after carotid endarterectomy. We will investigate whether a widely used antibiotic agent - minocycline - that has shown neuroprotective effects in animal models of neurological diseases - can reduce the cognitive deficits associated with the surgical procedure of carotid endarterectomy (CEA). Because these cognitive deficits are believed to be a result of small strokes (due to emboli and/or hypoperfusion), this study will provide preliminary data on the use of this drug as a neuroprotective agent in stroke - a leading cause of disability.
(1) The first aim of this study is to examine whether 5 doses of minocycline administered 36 hrs before and 1 dose 12 hrs after the surgical procedure in patients undergoing CEA are effective to reduce the cognitive deficits associated with this procedure as compared with placebo.
a. The null hypothesis is that there is no difference in cognitive performance changes after CEA between the patients that receive placebo or minocycline.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This protocol is a phase IIa study that will prospectively investigate whether minocycline (an antibiotic that showed neuroprotective effects in animal models) can decrease the cognitive deficits associated with carotid endarterectomy. This trial will be a randomized, parallel-group design, double-blind, placebo controlled clinical trial conducted at the Brigham and Women's Hospital.
The principal aim of this investigation is to study the effects of minocycline on cognitive performance after carotid endarterectomy. To measure cognitive function, we will perform a neuropsychological battery of tests (as detailed below). This battery of tests will be carried out by a blinded rater (a neurologist) and will be performed according to the following timetable:
Training session: before the baseline, patients will perform the tasks several times until they reach a stable plateau (defined as a variation of less than 10% in the last three trials) in order to eliminate the confounding effect of learning.
Baseline evaluation: the baseline evaluation will be performed in the day prior to the surgery.
Post-treatment evaluation: post-treatment evaluation will be performed 24 hours after the surgical procedure by the same blinded rater.
Neuropsychological battery of tests: we based our neuropsychological battery of tests on a similar study that evaluated the cognitive deficits associated with CEA and will consist of the following tests:
- Trail making test - parts A and B (this test evaluates visual concept and visuo-motor track)
- Controlled Oral Word Association (letters C, F and L) (this test evaluates verbal fluency)
- The Boston Naming Test (naming of 60 pictures) (this test evaluates left hemisphere damage)
- Digit Span Forward and Backward (this test evaluates working memory)
- Stroop Task (this test evaluates selective attention and mental flexibility)
- Mini-mental state examination (this test evaluates an adult patient's level of global cognitive functioning)
Blood sample analysis: As a secondary outcome, we will analyze subjects blood sample in respect to two particular substances: S100B and neuron specific enolase. The rationale for performing proteomic studies is that past research has shown that subtle cerebral injuries after carotid endarterectomy, even in the absence of stroke, might be associated with a significant increase in serum S100B (Connolly, 2001 - Neurosurgery, 2001 49 (5)) and also in traumatic brain injury (Cotena, 2006, J Neurosurg 2006 104 (6)). In addition, neuron specific enolase (NSE) also seems to be valuable to predict brain damage in patients with brain traumatic injury (Naeimi, 2006 - Brain Inj 2006 20(5)), thus showing that these two substances might be important biomarkers to be investigated in our study.
After eligibility screening (inclusion and exclusion criteria), consent form, medical history and physical exam participants will be randomized to the exposure - minocycline or placebo. The pills (minocycline and placebo) will have the same appearance and only one person will know whether the treatment is active or placebo.
Randomization:
Because our sample size will be relatively small, participants will be randomized to minocycline or placebo through a randomization stratification approach. This approach will ensure that both groups will have a similar distribution regarding baseline performance in the cognitive tests. Participants will be gathered into groups (strata) defined by their performance in the neuropsychological tasks (baseline). Participants within each stratum will be randomized to one of two treatment groups - minocycline and placebo - according to a block randomization of four and using a randomization list generated by a computer that will take into account the study entrance order. These groups are defined as follows:
Minocycline: we will use the dosage of minocycline that is currently used for clinical indications and also used in trials employing this drug as an anti-inflammatory agent. Minocycline will be administered in the period of 36 hrs before surgery (100 mg twice a day and 200 mg in the morning of the surgery - total of 5 doses) and 12 hrs after surgery (single dose of 100 mg).
The two doses of minocycline administered in the morning of the surgery will be taken with a small sip of water.
Placebo: placebo pill will have the same appearance as the real drug (minocycline) and will be administered using the same timetable as the active drug.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with carotid stenosis 60% or more with a clinical indication of CEA.
- Patients that can perform the tests in English.
- Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test (adequate birth control includes use of intra uterine device, or a barrier method, e.g. condom, diaphragm).
- Ages Eligible for Study: 18 Years - 90 Years
- Genders Eligible for Study: Both
Exclusion Criteria:
- Known hypersensitivity to tetracyclines
- Advanced cardiac, pulmonary or renal disease as assessed by the PCP of the patient.
- Previous strokes with important clinical neurological deficits.
- Pregnancy, breast-feeding or lactating
- Baseline MMSE score less or equal to 20.
- Female subjects on oral contraceptives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Minocycline arm
Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
|
100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
Other Names:
|
Placebo Comparator: Placebo arm
Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
|
1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neuropsychological assessment
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Friedlander, MD, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-P-001225
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carotid Stenosis
-
Heinrich-Heine University, DuesseldorfRecruitingCarotid Artery Plaque | Carotid Artery Diseases | Carotid Artery Stenosis Asymptomatic | Carotid Artery StenosisGermany
-
Xuanwu Hospital, BeijingChanghai Hospital; Peking Union Medical College Hospital; The Second Hospital... and other collaboratorsRecruitingCarotid Artery Stenting | Carotid Endarterectomy | Best Medical Treatment | Carotid Artery Stenosis AsymptomaticChina
-
Xuanwu Hospital, BeijingRecruitingRadiation-induced Carotid Artery StenosisChina
-
Centre Hospitalier St AnneHôpitaux Universitaires Paris Ile-de-Franc OuestNot yet recruiting
-
Ochsner Health SystemWithdrawnTCD | Symptomatic Carotid Stenosis | Asymptomatic Carotid Stenosis | HITSUnited States
-
University of BolognaActive, not recruiting
-
W.L.Gore & AssociatesCompleted
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center and other collaboratorsRecruitingCarotid Atherosclerosis | Asymptomatic Carotid Artery Stenosis | Carotid Artery AtheromaUnited States
-
Aesculap AGEnrolling by invitationCarotid Artery Stenosis | Iliac Artery Stenosis | Femoral Artery StenosisGermany
-
Mayo ClinicRecruitingPatients With Any Degree of Carotid Artery Stenosis and Vulnerable Features in the Carotid Artery PlaqueUnited States
Clinical Trials on Minocycline
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
State University of New York - Downstate Medical...RecruitingAsthma | Allergic RhinitisUnited States
-
Central South UniversityCompleted
-
OraPharmaCompleted
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
University of PittsburghTerminated
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
University of South FloridaCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina